Live talk

Join us every other Thursday at 3:00 pm PST for a discussion on the latest developments in the management and treatment of pituitary disease with leading specialists and experts in the field.  Stay tuned for an announcement on our next program   click here to join the studio

Read more about Live Talk here  –  Listen to our past sessions on demand.

News In Brief

Crinetics Pharmaceuticals announces  Phase 3 PATHFNDR-1 study complete; PATHFNDR-2 study of oral paltusotine for acromegaly enrollment ongoing, and anticipates seeking FDA application submission in 2024.  Learn more about  #paltusotine and #acromegaly. …Read more

Recordati Rare Diseases Introduces Cushing’s Conversations, a new support program for people who have been prescribed  ISTURISA®.   Read more

Amryt Pharma relaunches its patient-facing website for Mycapssa

Corcept Therapeutics announces new communication materials for Phase 3 Trial of Relacolirant in patients with Cushing’s syndrome.  Click here to learn more and see if you qualify. 

The Podcast

Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.

In our first live-talk session of 2023, we focus on critical topics, including insurance delay trends affecting pituitary medical practices, interesting clinical cases we can learn from, where telemedicine is going after the Covid era, and more commentary from the subjects we covered in our recent "briefing and insights" article.

Today we present an excellent discussion with Dr. Alan Krasner, Chief Medical Officer for Crinetics Pharmaceuticals. Dr. Krasner speaks to PWN about two very important drugs currently under development.

Subscribe & Listen

Live Talk on Demand